|
RNF2 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.313800E-02 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.273600E-02 |
| Normal-vs-Stage2 |
1.461840E-02 |
| Normal-vs-Stage3 |
4.342400E-02 |
| Normal-vs-Stage4 |
5.117800E-03 |
| Stage1-vs-Stage2 |
4.367000E-01 |
| Stage1-vs-Stage3 |
8.878600E-01 |
| Stage1-vs-Stage4 |
2.080600E-01 |
| Stage2-vs-Stage3 |
5.581400E-01 |
| Stage2-vs-Stage4 |
6.938200E-01 |
| Stage3-vs-Stage4 |
3.200800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.095900E-02 |
| Normal-vs-AfricanAmerican |
7.528400E-01 |
| Normal-vs-Asian |
3.499800E-02 |
| Caucasian-vs-AfricanAmerican |
2.095200E-01 |
| Caucasian-vs-Asian |
8.829400E-01 |
| AfricanAmerican-vs-Asian |
2.271400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.594400E-02 |
| Normal-vs-Female |
2.972200E-02 |
| Male-vs-Female |
7.323000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.822300E-02 |
| Normal-vs-Age(41-60Yrs) |
5.675500E-03 |
| Normal-vs-Age(61-80Yrs) |
4.418200E-02 |
| Normal-vs-Age(81-100Yrs) |
2.948000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.548640E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.502400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.822200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.647000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.538600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.779200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.835000E-01 |
| Classical-VS-Follicular |
4.624100E-03 |
| Classical-VS-Other |
2.438600E-01 |
| Classical-VS-Normal |
1.697780E-01 |
| Tall-VS-Follicular |
3.195200E-01 |
| Tall-VS-Other |
4.891600E-01 |
| Tall-VS-Normal |
1.226040E-01 |
| Follicular-VS-Other |
8.303600E-01 |
| Follicular-VS-Normal |
1.418650E-03 |
| Other-VS-Normal |
7.427900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.924400E-03 |
| Normal-vs-N1 |
6.439200E-03 |
| N0-vs-N1 |
7.687400E-01 |
|
|
